{"id":72335,"date":"2024-03-17T21:27:05","date_gmt":"2024-03-17T21:27:05","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/plamotamab-clinical-trials-global-bispecific-antibodies-market-drug-sales-report-2029\/"},"modified":"2024-03-17T21:27:05","modified_gmt":"2024-03-17T21:27:05","slug":"plamotamab-clinical-trials-global-bispecific-antibodies-market-drug-sales-report-2029","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/plamotamab-clinical-trials-global-bispecific-antibodies-market-drug-sales-report-2029\/","title":{"rendered":"Plamotamab Clinical Trials Global Bispecific Antibodies Market Drug Sales Report 2029"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<p align=\"justify\">Delhi, March  17, 2024  (GLOBE NEWSWIRE) &#8212; <strong><em>Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights:<\/em><\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Global Market Forecast Till 2029: &gt; USD 36 Billion<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Approved Bispecific Antibodies: 11<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Yearly &amp; Quarterly Sales Insight<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Global &amp; Regional Sales Insights<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Insight On Bispecific Antibodies In Clinical Trials: &gt; 600 Bispecific Antibodies<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Global Bispecific Antibodies Clinical Trials By Company, Indication &amp; Phase<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Fast Track Approval, Orphan Designation &amp; Priority Status Insights<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Approved Bispecific Antibodies Pricing\u00a0 &amp; Dosage Analysis<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Top 30 Companies Developing Bispecific Antibodies Competitive Insight<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">800 Pages Clinical &amp; Commercial Opportunity insight<\/li>\n<\/ul>\n<p align=\"justify\"><strong><em>Download Report:<\/em><\/strong><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jNLiIHA8kfa3LK_B3aV8b860oGcX1OhGux--iw0SPHn2IK0XpzGNMLPIJiBjGOwMYptdchA5KE8S0zdZyIXAsUypbQ2siQcCM8cSb-5Lau_187D3BHwBqReZg64y51mrvl6fvb2RLlu714tvXQWEU4nzBJNGeJ4lQK5Umx7Sszo0_2t6GERUcSAOrs834yNFFaKS3Xanq6IryPSR6Taf4w3gbOFv5AqAY544Cza2cfZTOoifvlGRSmVWLJYVJFa5zefvjnAn9uTBsQW6gwrM_w==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>https:\/\/www.kuickresearch.com\/report-bispecific-antibody-market-bispecific-antibodies-market<\/u><\/a><\/p>\n<p align=\"justify\">Xencor&#8217;s plamotamab represents a novel bispecific monoclonal antibody therapeutic candidate engineered to harness the immune system&#8217;s antitumor potential. This innovative molecule incorporates an Fc domain and exhibits dual antigen-binding specificity, a design strategy that confers it with prospective anti-cancer activity. One of plamotamab&#8217;s antigen-binding domains is directed against human CD3, a surface antigen expressed on T lymphocytes, while the other domain selectively recognizes and binds to human CD20, a tumor-associated antigen predominantly overexpressed on B cells across various developmental stages. Xencor has signed an exclusive collaboration and worldwide license agreement with Janssen Biotech for the development and commercialization of plamotamab.<\/p>\n<p align=\"justify\">The XmAb\u00ae Bispecific Fc Domain, a proprietary platform developed by Xencor, serves as the molecular scaffold underpinning plamotamab&#8217;s unique bifunctional design. This engineered Fc region not only enables the integration of the two distinct antigen-binding domains but also confers favorable pharmacokinetic properties on the antibody, including an extended circulating half-life, enhanced stability, and streamlined manufacturing processes. Upon systemic administration, plamotamab simultaneously engages with both T lymphocytes, via the CD3-targeting arm, and malignant B-lineage cells overexpressing the CD20 tumor-associated antigen.<\/p>\n<p align=\"justify\">This dual binding event initiates a potent antitumor immune response, wherein plamotamab facilitates the recruitment and activation of cytotoxic T cells against the CD20-positive cancer cell population. Notably, the presence of the Fc domain within plamotamab&#8217;s structure not only contributes to its prolonged persistence in circulation but also augments the T-cell-mediated cytotoxicity against tumor cells. This is achieved through Fc receptor binding, which potentiates effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), further amplifying the destruction of malignant B cells.<\/p>\n<p align=\"justify\">Safety and anti-tumor activity observed in the ongoing Phase 1 clinical trial suggest that plamotamab is generally well tolerated and exhibits promising clinical efficacy when used alone. Additionally, plamotamab is undergoing evaluation in a Phase 2 study, where it is being investigated in combination with tafasitamab plus lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma. This study comprises two segments \u2013 a safety run-in phase aimed at establishing the safety profile of the triple combination, followed by a two-arm, open-label cohort where patients will be randomized to receive either the triple combination or tafasitamab plus lenalidomide.<\/p>\n<p align=\"justify\">In conclusion, plamotamab stands at the forefront of innovative cancer therapies, showcasing promising safety profiles and encouraging clinical activity as demonstrated in Phase 1 trials. Its inclusion in Phase 2 studies, particularly in combination with established treatments for diffuse large B-cell lymphoma, highlights its potential to address unmet medical needs in challenging malignancies.<\/p>\n<pre\/>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Delhi, March 17, 2024 (GLOBE NEWSWIRE) &#8212; Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights: Global Market Forecast Till 2029: &gt; USD 36 Billion Approved Bispecific Antibodies: 11 Yearly &amp; Quarterly Sales Insight Global &amp; Regional Sales Insights Insight On Bispecific Antibodies In Clinical Trials: &gt; 600 Bispecific Antibodies Global Bispecific Antibodies Clinical Trials [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":72336,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/4b0593d4-0134-4313-866b-b56a11c71af7","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-72335","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/72335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=72335"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/72335\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/72336"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=72335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=72335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=72335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}